MP0317 + gemcitabine + cisplatin + durvalumab

This is a combination regimen consisting of four agents: - **MP0317** is a tumor-localized CD40 agonist DARPin (designed ankyrin repeat protein) that becomes active only in the presence of fibroblast activation protein (FAP), which is highly expressed by cancer-associated fibroblasts in the tumor microenvironment. This enables targeted activation of CD40, a pivotal immune activator, while limiting systemic toxicity. - **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis. - **Cisplatin** is a platinum-based chemotherapy that crosslinks DNA, leading to apoptosis. - **Durvalumab** is an anti-PD-L1 monoclonal antibody (checkpoint inhibitor) that blocks PD-L1 interaction with PD-1 and CD80 to promote anti-tumor immune activity. This specific combination is under clinical investigation—most notably in first-line treatment of advanced biliary tract cancer—aiming to maximize tumor immune activation in synergy with chemotherapy and checkpoint blockade[6][9].

Other names

MP0317 + gemcitabine + cisplatin + durvalumab